» Articles » PMID: 36112968

Long-term Follow-up of VIALE-C in Patients with Untreated AML Ineligible for Intensive Chemotherapy

Citing Articles

Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients.

Shen J, Shan M, Chu M, Cai Y, Rui J, Chen S Blood Cancer J. 2025; 15(1):17.

PMID: 39934109 PMC: 11814316. DOI: 10.1038/s41408-025-01227-7.


The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.

DiNardo C, Pratz K, Panayiotidis P, Wei X, Vorobyev V, Illes A Am J Hematol. 2024; 100(1):185-188.

PMID: 39487568 PMC: 11625987. DOI: 10.1002/ajh.27515.


Mitochondria and Acute Leukemia: A Clinician's Perspective.

Iyer P, Jasdanwala S, Bhatia K, Bhatt S Int J Mol Sci. 2024; 25(17).

PMID: 39273651 PMC: 11395402. DOI: 10.3390/ijms25179704.


Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET CC-96191.

Lunn-Halbert M, Laszlo G, Erraiss S, Orr M, Jessup H, Thomas H Cancers (Basel). 2024; 16(5).

PMID: 38473239 PMC: 10931532. DOI: 10.3390/cancers16050877.


Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies.

Wang B, Reville P, Yassouf M, Jelloul F, Ly C, Desai P Nat Commun. 2024; 15(1):1821.

PMID: 38418901 PMC: 10902356. DOI: 10.1038/s41467-024-45916-6.